Subthreshold Change in Glycated Hemoglobin and Body Mass Index After the Initiation of Second-Generation Antipsychotics Among Patients With Schizophrenia or Bipolar Disorder: A Nationwide Prospective Cohort Study in Japan

Ryo Sawagashira, MD; Ryodai Yamamura, PhD; Ryo Okubo, PhD, MD; Naoki Hashimoto, PhD, MD; Shuhei Ishikawa, PhD; Yoichi M. Ito, PhD; Norihiro Sato, PhD, MD; Ichiro Kusumi, PhD, MD

J Clin Psychiatry 2022;83(3):21m14099

ABSTRACT

Objective: The risk of diabetes development has been reported to differ among second-generation antipsychotics (SGAs). However, few studies have focused on the subthreshold change in glycated hemoglobin (HbA_1c). Therefore, this study examined the subthreshold change in HbA_1c and change in body mass index (BMI) 3 months after patients initiated one of 6 SGAs widely prescribed in Japan.

Methods: This is a prospective cohort study of patients followed up based on the Japanese blood glucose monitoring guidelines for patients with schizophrenia. We collected eligible patients’ demographic data, medication history, blood tests, and weight measurements both at baseline and 3 months after recruitment, between April 2013 and March 2015. In the 378 patients with schizophrenia, schizoaffective disorder, and bipolar disorder based on ICD-10, we compared the subthreshold change in HbA_1c and the change in BMI 3 months after antipsychotic initiation by using multivariate regression analysis.

Results: The subthreshold change in HbA_1c 3 months after initiating blonanserin was significantly lower compared with olanzapine (B = −0.17, 95% CI = −0.31 to −0.04). In addition, the change in BMI 3 months after initiating blonanserin and aripiprazole was significantly lower compared with olanzapine (B = −0.93, 95% CI = −1.74 to −0.12; B = −0.71, 95% CI = −1.30 to −0.12, respectively).

Conclusions: This is the first study to clarify the differences in the subthreshold change in HbA_1c among SGAs. Our results suggest that blonanserin is likely to be a favorable treatment for patients with high risk of diabetes.

Trial Registration: UMIN Clinical Trial Registry identifier: UMIN000009868

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (41)

Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. PubMed CrossRef
Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatr Scand. 2018;138(6):492–499. PubMed CrossRef
Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627. PubMed CrossRef
De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126. PubMed CrossRef
Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2(5):452–464. PubMed CrossRef
Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235. PubMed CrossRef
Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166–174. PubMed CrossRef
Cao H, Meng Y, Li X, et al. The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting. J Psychiatr Res. 2020;129:265–271. PubMed CrossRef
Godin O, Leboyer M, Schürhoff F, et al; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Predictors of rapid high weight gain in schizophrenia: longitudinal analysis of the French FACE-SZ cohort. J Psychiatr Res. 2017;94:62–69. PubMed CrossRef
Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res. 2012;46(4):540–548. PubMed CrossRef
Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191(1):23–29. PubMed CrossRef
Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171–179. PubMed CrossRef
Hirsch L, Yang J, Bresee L, et al. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40(9):771–781. PubMed CrossRef
Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–811. PubMed CrossRef
Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A_1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry. 2007;68(4):533–541. PubMed CrossRef
Steylen PM, van der Heijden FM, Hoogendijk WJ, et al. Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study. Diabetes Metab Syndr Obes. 2015;8:57–63. PubMed CrossRef
Mitchell AJ, Vancampfort D, Manu P, et al. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? a large observational study. PLoS One. 2019;14(9):e0210674. PubMed CrossRef
Lee SY, Park MH, Patkar AA, et al. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):490–496. PubMed CrossRef
Osborn DP, Petersen I, Beckley N, et al. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. J Psychopharmacol. 2018;32(10):1098–1103. PubMed CrossRef
Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65–84. PubMed CrossRef
Onrust SV, McClellan K. Perospirone. CNS Drugs. 2001;15(4):329–337, discussion 338. PubMed CrossRef
Kishi T, Ikuta T, Matsunaga S, et al. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat. 2017;13:1281–1302. PubMed CrossRef
Kusumi I, Arai Y, Okubo R, et al. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder. BJPsych Open. 2018;4(6):454–460. PubMed CrossRef
Kusumi I, Ito K, Honda M, et al. Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data. Psychiatry Clin Neurosci. 2011;65(4):349–355. PubMed CrossRef
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization; 1992.
Dong M, Zeng L-N, Zhang Q, et al. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. Asian J Psychiatr. 2019;45:74–80. PubMed CrossRef
Yoshio T, Inada T, Uno J, et al. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol. 2012;27(1):70–75. PubMed CrossRef
Tahara Y, Shima K. Kinetics of HbA_1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18(4):440–447. PubMed CrossRef
Hirst JA, Stevens RJ, Farmer AJ. Changes in HbA_1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change. PLoS One. 2014;9(3):e92458. PubMed CrossRef
Kameyama M, Okumiya T, Tokuhiro S, et al. Estimation of the hemoglobin glycation rate constant. Sci Rep. 2021;11(1):986. PubMed CrossRef
Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997–2004. PubMed CrossRef
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2017.
Kishi T, Matsuda Y, Iwata N. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e88049. PubMed CrossRef
Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208–224. PubMed CrossRef
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. PubMed CrossRef
Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. PubMed CrossRef
Rico-Villademoros F, Calandre EP. Risk of bias in observational studies of interventions: the case of antipsychotic-induced diabetes. Lancet Psychiatry. 2016;3(2):103–104. PubMed CrossRef
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. PubMed CrossRef
Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1-3):103–110. PubMed CrossRef
Luckhoff H, Phahladira L, Scheffler F, et al. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophr Res. 2019;206:171–176. PubMed CrossRef
Maxwell SE. Sample size and multiple regression analysis. Psychol Methods. 2000;5(4):434–458. PubMed CrossRef